CF PHARMTECH (02652) has announced that the Investigational New Drug (IND) application for its self-developed inhalation powder candidate, ICF001, has been accepted by the National Medical Products Administration (NMPA) of China. ICF001 is an innovative long-acting dry powder inhaler candidate developed based on a prodrug technology platform, specifically designed for treating pulmonary arterial hypertension and related severe lung diseases. In terms of molecular design and mechanism of action, the product converts active molecules into prodrugs through specific chemical modifications. After inhalation and deposition in the lungs, it relies on the slow cleavage by endogenous enzymes in lung tissue to sustainably release the active ingredient. Preclinical studies suggest that this design is expected to deliver the drug to deep lung tissue while moderating the initial peak plasma concentration (Cmax) and extending local drug exposure time, thereby exploring the potential to optimize the drug's pharmacokinetic (PK) profile. The primary indications for ICF001 are pulmonary arterial hypertension (PAH; WHO Group 1) and pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3). PAH is a fatal rare disease, while PH-ILD represents a field with a larger patient population and relatively limited existing therapies. Recent cutting-edge scientific research and clinical exploration of similar international projects further indicate that the specific pathway targeted by ICF001 has dual potential for anti-pulmonary hypertension and anti-fibrotic effects. Therefore, based on this unique mechanism, ICF001 has future potential to expand into broader patient populations, such as those with interstitial lung disease-related pulmonary fibrosis, including idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). The acceptance of this application marks a significant milestone for the group in advancing its high-barrier respiratory pipeline into clinical development. The company believes that the strategic focus of ICF001's development lies in exploring potential improvements in tolerability and titration efficiency, specifically concentrating on the following areas: First, through the synergistic optimization of molecular structure and formulation processes, it aims to enhance drug loading efficiency, reduce the burden of administration, and improve airway tolerance. Second, it seeks to optimize in vivo exposure characteristics by controlling the peak plasma concentration while improving overall exposure performance to support a more controllable dosing strategy. If the related mechanisms and clinical benefits are further confirmed in subsequent studies, it is expected to support a more operable and controllable inhalation dosing strategy, enhance long-term medication adherence, optimize the potential for efficacy, and expand the drug's clinical accessibility.